Moneyta · stock research · no sign-up needed
ABT
FollowFigures below come straight from SEC filings: every number is the company's own, on the record.
Revenue (Q1 FY2026)
$11.2B
+1.7% y/y
Net income (Q1 FY2026)
$1.1B
as filed with the SEC
Institutions holding
2,981
-138 last quarter
Overview · Abbott Laboratories
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndro…
Management team
- Ms. Lisa D. Earnhardt · Executive VP & Group President of Medical DevicesFind on LinkedIn
- Mr. Daniel Gesua Sive Salvadori · Executive VP and Group President of Established Pharmaceuticals & Nutritional ProductsFind on LinkedIn
- Mr. Hubert L. Allen J.D. · Executive VP, General Counsel & SecretaryFind on LinkedIn
- Mr. Philip P. Boudreau · CFO & Executive VP of FinanceFind on LinkedIn
Start free to see the full management team.
Links open LinkedIn searches, not verified profiles. Team data from our market-data vendor's company profile.
What history says when its signals fire
Every signal Moneyta surfaces carries its full base-rate history: how often it beat the index, and how often it didn't. See the evidence
The desk's Snapshot
3 of 15 open to everyone · members see allRead the full desk report on ABT
Seven analysts, the debate, the risk review, every claim cited. And the same for every name you hold.
Free plan, no credit card required. Silver opens the full report, $19.99 a month. AI-written · every claim cites a source · Insight, not advice.
The full desk report
Seven AI analysts read the filings and argue both sides. What survives, with every claim cited, for members.
Who holds it, who's buying Gold
Full holder table, quarter-over-quarter flows, insider transactions, and the conviction screen.
Largest holder
Net flow last quarter
Insider buys, 90d
Further reading
Source: SEC EDGAR (XBRL company facts, form 13F-HR). Educational analysis of published data: insight, not advice.